Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.45 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14164240 | 0.85 | LMNA (0.44) | LMNANPSR1NCOA1NCOA3PPARG | |
| SCHEMBL19475255 | 0.85 | NCOA1 (0.44) | LMNANPSR1NCOA1NCOA3PPARG | |
| SCHEMBL24667434 | 0.84 | HCAR2 (0.55) | LMNAFFAR2HCAR2KDM4EMAPT | |
| SCHEMBL3123965 | 0.79 | KDR (0.39) | CSNK2A2KDRCSNK2BCSNK2A1FFAR2 | |
| SCHEMBL25224893 | 0.76 | ALDH1A1 (0.43) | LMNANPSR1NCOA1NCOA3PPARG | |
| SCHEMBL567672 | 0.76 | HCAR2 (0.34) | NPSR1HCAR2MAPTALDH1A1MAPK1 | |
| SCHEMBL1107386 | 0.74 | HCAR2 (0.68) | LMNANPSR1NCOA1NCOA3PPARG | |
| SCHEMBL472995 | 0.74 | CSNK2A2 (0.42) | LMNANPSR1NCOA1NCOA3PPARG | |
| SCHEMBL4292895 | 0.74 | HCAR2 (0.42) | LMNANPSR1NCOA1NCOA3PPARG | |
| SCHEMBL16742919 | 0.74 | FFAR2 (0.45) | LMNANPSR1NCOA1NCOA3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280476-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| WO-2020102096-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280476-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | LMNA 1423/4885NPSR1 2433/4885NCOA1 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.